Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CDA | P32320 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19807415 | 1.00 | SLC29A1 (0.47) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 | |
| SCHEMBL16310899 | 1.00 | SLC29A1 (0.47) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 | |
| SCHEMBL25612157 | 1.00 | SLC29A1 (0.47) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 | |
| SCHEMBL16311131 | 1.00 | SLC29A1 (0.47) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 | |
| SCHEMBL16138522 | 0.91 | LMNA (0.39) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 | |
| SCHEMBL23836636 | 0.89 | SLC29A1 (0.47) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 | |
| SCHEMBL16138518 | 0.89 | SLC29A1 (0.47) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 | |
| SCHEMBL19464871 | 0.89 | SLC29A1 (0.47) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 | |
| SCHEMBL16311135 | 0.89 | SLC29A1 (0.47) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 | |
| SCHEMBL19807372 | 0.89 | SLC29A1 (0.47) | SLC29A1SLC28A1SLC28A2SLC28A3SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135611-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2022-05-05 | — | — | US | disclosed |
| US-11124536-B2 | Uridine nucleoside derivatives, compositions and methods of use | TUFTS UNIVERSITY (US) | 2021-09-21 | — | — | US | disclosed |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200399302-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10544183-B2 | Uridine nucleoside derivatives, compositions and methods of use | TUFTS UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124536-B2 | Uridine nucleoside derivatives, compositions and methods of use | P2RY6, UPP1, UMPS | SLC29A1 54/4885SLC28A1 159/4885SLC28A2 85/4885 |
| US-20200399302-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | SLC29A1 54/4885SLC28A1 159/4885SLC28A2 85/4885 |
| US-10544183-B2 | Uridine nucleoside derivatives, compositions and methods of use | P2RY6, UPP1, UMPS | SLC29A1 54/4885SLC28A1 159/4885SLC28A2 85/4885 |
| US-20220135611-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | SLC29A1 54/4885SLC28A1 159/4885SLC28A2 85/4885 |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | SLC29A1 2267/4885SLC28A1 1459/4885SLC28A2 1402/4885 |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | SLC29A1 2267/4885SLC28A1 1459/4885SLC28A2 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.